DRMA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.0M
+56.4%
1.9M
+1.4%
1.9M
+7.9%
1.8M
-0.7%
1.8M
R&D
212.6K
-44.6%
383.7K
-27.1%
526.6K
+4.4%
504.4K
-18.4%
617.8K
SG&A
2.8M
+81.6%
1.5M
+12.3%
1.4M
+9.4%
1.3M
+8.8%
1.2M
Operating Income
-3013567
-56.4%
-1926382
-1.4%
-1900393
-7.9%
-1760671
+0.7%
-1772731
EBITDA
-3013567
-56.4%
-1926382
-1.4%
-1900393
-7.9%
-1760671
+0.7%
-1772731
Net Income
-2967063
-60.6%
-1847706
+0.8%
-1861888
-10.0%
-1691989
+0.5%
-1701093
EPS (Basic)
$-0.74
-54.2%
$-0.48
+70.7%
$-1.64
+0.6%
$-1.65
+0.6%
$-1.66
EPS (Diluted)
$-0.74
-54.2%
$-0.48
+70.7%
$-1.64
+0.6%
$-1.65
+0.6%
$-1.66
Shares (Diluted)
4.0M
+4.2%
3.9M
+239.6%
1.1M
+10.7%
1.0M
-0.0%
1.0M
Dermata Therapeutics (DRMA) โ€” Financials